Page 1 - Kipaji Newsletter - Edition 1
P. 1

THE COMMUNITY ENGAGEMENT & ADVOCACY NEWSLETTER OF THE BRILLIANT CONSORTIUM    |    EDITION 1    |    www.africanalliance.org.za    |    @The-African-Alliance    |    2024
     THE BIRTH OF  AN  AFRICAN                                                    CUTTING THROUGH THE

     CONSORTIUM TO DISCOVER                                                       JARGON  &  GETTING  TO
                                                                                  THE POINT!
     AN HIV VACCINE                                                               From the proposal  development stage we


                                                                                  knew that one thing we would need to get
     What happens when some of the best minds in HIV  Vaccine  research come  together  to   right was building  our  collective  literacy
     respond to a USAID Notice  of  Funding Opportunity? The BRILLIANT  Consortium  is born!   in vaccinology and immunology. As a first
     Successfully applying for a cooperative agreement to implement the HIV Vaccine Innovation,   step we identified a selection of key terms
     Science, and Technology Acceleration in Africa (HIV-VISTA) Project, this diverse group of   that matter to us in BRILLIANT, broke them
     partners co-created a proposal, characterized by deeply thoughtful Community Engagement,     down just for you, and thought about this
     to spearhead  vaccine  development,(including  immunogen and adjuvant design and   all! In this explainer set we check out over
     identification  of  appropriate  platforms  and  delivery  mechanisms);  conduct  preclinical   40 terms and cut through the jargon to tell
     studies to determine the safety, toxicity and immunogenicity of immunogens and adjuvants   you why they matter  - and why we  care!
     in animal studies; and finally conduct clinical trials using novel vaccine formulations, adjuvant   Check out the full set in our next newsletter!
     combinations and delivery methods.



























      A BRILLIANT


      PARTNERSHIP



      On the 21st of September 2023, the South African Medical
      Research Council, announced  that the U.S. Agency  for
      International  Development  (USAID)  had awarded the
      BRILLIANT  Consortium up  to US$45  million  to implement
      the HIV Vaccine Innovation, Science, and Technology
      Acceleration in Africa (HIV-VISTA) programme.


      (L-R) Paloma Adams-Allen (Deputy Administrator of the USAID), Prof Glenda
      Gray (SAMRC  President  and CEO) and Reuben  Brigety  (United  States
      Ambassador to South Africa.



                                                                                                    This newsletter is
                                                                                                    compiled by the African
                                                                                                    Alliance, GALZ and
                                                                                                    MURWP, the BRILLIANT
                                                                                                    Consortium’s
                                                                                                    Community
                                                                                                    Engagement
                                                                                                    Leadership Team.
   1   2   3   4